…
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Lifeline Biotechnologies Inc is an OTC Pink–listed company (LLBO.US); public filings and disclosures about its operations, products and financial condition are limited, so its core business is not well documented. Long-term growth would depend on successful development or commercialization of any biotechnological assets, regulatory approvals, strategic partnerships and reliable access to capital, which may benefit future expansion.
The most important investment risks are very limited public disclosure and low trading liquidity combined with high execution and financing risk tied to regulatory and clinical development outcomes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.06M | -0.01M | -0.00M | -0.01M | - |
| Net income | -0.06M | -0.01M | -0.00M | -0.01M | - |
| Ebitda | -0.06M | -0.01M | -0.00M | -0.01M | - |
| Depreciation and amortization | - | - | - | 0.23M | 0.24M |
| Operating income | -0.06M | -0.01M | -0.00M | -0.01M | - |
| Other operating expenses | 0.06M | 0.01M | 0.00M | 0.01M | - |
| Total operating expenses | 0.06M | 0.01M | 0.00M | 0.01M | - |
| Total other income expense net | - | - | 0.00M | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2018-12-31 |
| Total assets | - | - | - | - | 0.44M |
| Other current assets | - | - | - | - | 0.00M |
| Total liab | - | - | - | - | 0.39M |
| Total stockholder equity | - | - | - | - | 0.06M |
| Other current liab | - | - | - | - | 0.00M |
| Common stock | - | - | - | - | 0.03M |
| Retained earnings | - | - | - | - | -14.27M |
| Cash | - | - | - | - | 0.00M |
| Total current liabilities | - | - | - | - | 0.39M |
| Current deferred revenue | - | - | - | - | 0.00M |
| Net debt | - | - | - | - | 0.33M |
| Short term debt | - | - | - | - | 0.33M |
| Short long term debt total | - | - | - | - | 0.33M |
| Other stockholder equity | - | - | - | - | -0.03M |
| Total current assets | - | - | - | - | 0.18M |
| Net receivables | - | - | - | - | 0.18M |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | - | - | - | - | 0.06M |
| Accumulated other comprehensive income | - | - | - | - | 14.33M |
| Non currrent assets other | - | - | - | - | 0.00M |
| Non current assets total | - | - | - | - | 0.26M |
| Breakdown | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
| Total cashflows from investing activities | - | -0.08M | - | - | - |
| Total cash from financing activities | - | -0.06M | -0.05M | 0.10M | -0.05M |
| Net income | - | -0.04M | 0.24M | 0.01M | 0.00M |
| Change in cash | - | 0.00M | -0.00M | 0.00M | 0.00M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| End period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total cash from operating activities | - | 0.14M | 0.05M | -0.10M | 0.05M |
| Depreciation | - | - | 0.00M | 0.00M | 0.00M |
| Change to account receivables | - | 0.15M | -0.19M | -0.11M | 0.05M |
| Other cashflows from financing activities | - | -0.06M | -0.05M | 0.10M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | - | 0.18M | -0.20M | -0.11M | 0.05M |
| Other non cash items | - | -0.18M | 0.20M | 0.11M | -0.04M |
| Free cash flow | - | 0.14M | 0.05M | -0.10M | 0.05M |
Sector: Financial Services Industry: Shell Companies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| LLBO Lifeline Biotechnologies Inc |
-0.00 25.00% |
0.00 | - | - | - | - |
| CLUS CLUS |
- -% |
200.00 | - | - | 0.09 | 0.92 |
| SGDH Sgd Holdings Ltd |
- -% |
0.02 | - | - | 59741.55 | 0.56 |
| LION Lionsgate Studios Holding Corp. |
- -% |
13.74 | - | 23.31 | 1.13 | 1.35 |
| QKIE QKIE |
- -% |
1.94 | - | - | 470.20 | - |
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.
| Name | Title | Year Born |
|---|---|---|
| Mr. James D. Holmes CPA, MBA | Chairman, Chief Exec. Officer and Treasurer | NA |
| Dr. William H. Reeves Ph.D. | Founder | NA |
| Dr. Louis G. Keith M.D., Ph.D. | VP, Medical Director, Sec. and Director | NA |
| Mr. James D. Holmes CPA, MBA | Treasurer & Chairman | NA |
| Ms. Caren D. Currier | President & CEO | 1963 |
| Dr. Louis G. Keith M.D., Ph.D. | Vice President, Medical Director, Secretary and Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.